Determination of Iron Absorption and Losses in People Living at High Altitude to Investigate the Requirements in This Population Group Using a Newly Developed Technique
NCT ID: NCT07142590
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
120 participants
INTERVENTIONAL
2025-08-22
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Altitude on Iron Absorption in Iron Depleted Women
NCT05500014
Intravenous Iron Effects on Performance at High Altitude
NCT06686693
Assessing the Immediate Increase in Serum Ferritin After Oral Iron Doses: an Experimental Study in Iron-deficient Women
NCT06851130
Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation
NCT01785407
Iron Long-Term Labelling Study Switzerland
NCT02979132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will collect blood samples during the second year from study start at a frequency of 4 months for a total of 4 visits, at months 12, 16, 20 and 24. Venous blood samples for the measurement of the isotopic signal will be collected, and at two additional study visits the investigators will also measure hemoglobin using the so-called carbon monoxide (CO) rebreathing method that includes a CO rebreathing into a closed-circuit system in combination with pure oxygen. Before and after the 6 min re-breathing, capillary blood will be collected by finger prick in triplicates. At the study visits with blood withdrawal, the investigators will ask participants to fill questionnaires about dietary intake and physical activity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Isotopic labeled participants
The two groups of participants differ only for their residence location at different altitudes. The intervention (administration of iron isotopes) does not differ among the two groups.
Stable Isotopes
15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stable Isotopes
15 mg of stable iron isotopes in the form of ferrous sulphate 57FeSO4 will be orally administered to each participant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI: 18 to 25 kg/m2
* Body weight \<70 kg for females, \<85 kg for males
* Plasma ferritin \>25 µg/L
* Signed informed consent
Exclusion Criteria
* Inflammation (CRP \> 5 mg/L)1
* Plasma ferritin \>150 µg/L for females and \>200 µg/L for males
* Chronic disease known to affect iron metabolism
* Chronic medications (except for oral contraceptives)
* Pregnancy (tested at screening) or intention to become pregnant during the course of the study
* Lactation
* High physical activity (MET-min/week \> 3000 calculated according to the IPAQ, short version, administered at the screening)
* Difficulty with blood withdrawal
* Earlier participation in a study using stable iron isotopes or participation in any clinical study within the last 30 days
* Smoking
* Blood donation, blood transfusion or significant blood loss (more than 400 mL) over the past 6 months
* Intention to regularly donate blood during the 2 years duration of the study
* No residence in the respective location/altitude for at least the last 2 years
* No intention to reside in the respective location/altitude at least for the next 2 years
* Participants who are planning to spend an extended period (\>12 weeks) at a different altitude from their residence location
* Spending more than 2 nights per week at a different location from residence location
* Inability to understand the information sheet and the informed consent form due to cognitive or language reasons
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss Federal Institute of Technology
OTHER
University of Lausanne
OTHER
Diego Moretti
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diego Moretti
Prof. Dr. Diego Moretti
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diego Moretti, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Fernfachhochschule Schweiz (FFHS), SUPSI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fernfachhochschule Schweiz (FFHS)
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Iron_ARIA_2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.